Previous Close | 0.4550 |
Open | 0.4470 |
Bid | 0.4600 x 100 |
Ask | 0.0000 x 0 |
Day's Range | 0.4450 - 0.5200 |
52 Week Range | 0.3920 - 4.6900 |
Volume | |
Avg. Volume | 1,183,783 |
Market Cap | 10.861M |
Beta (5Y Monthly) | 1.47 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7500 |
Earnings Date | Apr 26, 2024 - Apr 30, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.50 |
Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, versus 14.3% of patients on placebo. 20% of patients treated with eblasakimab achieved EASI-100 (100% reducti
SAN MATEO, Calif. and SINGAPORE, April 19, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it received a letter (the “Letter”) on April 18, 2024 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Mark
In a preliminary review of blinded data from the ongoing TREK-DX study, 45% (10/22) of patients achieved at least a 90% reduction in their EASI score (EASI-90) after 16 weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks. Topline, unblinded data from the full dataset expected at the end of 2024.Phase 2 proof-of-concept trial of farudodstat in alopecia areata